Medical Devices

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

With major investor conferences ahead, Ceribell showcases impressive revenue growth fueled by its AI-driven EEG system and a string of new FDA clearances.

A landmark deal with Abu Dhabi's SSMC will make the UAE a regional hub for Nyxoah's innovative Genio implant, targeting a major health issue.

The NYSE-listed medtech firm will detail its "ecosystem" strategy for the booming shoulder surgery market amid rapid revenue growth and a push for profitability.

With COVID revenue fading, QuidelOrtho will use a key conference to prove its diversified diagnostics model can deliver on growth, margins, and cash flow.

The Nashville-based clinic brings its luxury, results-driven skincare model to Arlington, VA, tapping into national wellness trends and rapid growth.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

The latest astronaut crew on the ISS is conducting cutting-edge research in microgravity, aiming to revolutionize healthcare and environmental tech on Earth.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

After two decades of global use, Fziomed's anti-adhesion gel has treated one million patients, signaling a major shift in post-surgical recovery.

The prestigious medical center's adoption of the XTRAC laser signals a major shift in treating chronic skin disease and expands hope for millions of patients.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

The NYC-based private equity firm's oversubscribed Fund IX far exceeds its predecessor, showing robust investor confidence in its long-term strategy.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.

AcuityMD's new Salesforce integration promises to eliminate data silos and boost sales for MedTech firms, marking a strategic leap for the AI unicorn.

A new AI-native system, Isaac PracticeOS, promises to replace up to ten dental software tools, automating claims, scheduling, and patient communications.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

Photocure reports robust Q4 earnings and a strong 2026 forecast, while pivoting to an AI-driven future for bladder cancer diagnostics and global expansion.